Launch of gastrointestinal prokinetic agents: NAUZELIN^® OD Tablets 5 and NAUZELIN^® OD Tablets 10

Tokyo, Japan, December 5, 2011 --- Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") started sales of NAUZELIN^® OD Tablets formulation, including NAUZELIN^® OD Tablets 5 and NAUZELIN^® OD Tablets 10.

Domperidone, the principal active component of NAUZELIN^®, has high clinical efficacy due to its strong antiemetic and gastrointestinal motor-stimulating activities, and is in wide use for treating diseases of the gastrointestinal tract. NAUZELIN^® is already available as tablets, granules, dry syrup, and suppositories, and a fifth formulation, orally disintegrating (OD) tablets, has now been launched.

NAUZELIN^® OD Tablets, a new orally disintegrating tablet formulation, have been developed independently by Kyowa Hakko Kirin, using the latest technology, including Solblet^®, for which Kyowa Hakko Kirin holds the patent. The tablets are characterized in dissolving rapidly in the mouth while having approximately the same hardness as ordinary tablets. They are appropriate for use by patients who have difficulty swallowing, such as infants and elderly people, and by people in workplaces or other situations where it is difficult to access or drink water. NAUZELIN^® is considered to support an improved quality of life for people suffering from chronic gastritis.

Kyowa Hakko Kirin is developing therapeutic antibodies driven by state-of-the art antibody technologies mainly in the core therapeutic areas of oncology, nephrology and immunology. Kyowa Hakko Kirin also contributes to worldwide human health through innovative small-molecular drug discovery.